Items where Funder is Millennium Pharmaceuticals Inc..
![[up]](/style/images/multi_up.png)
Up a levelA19272
Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026
A24078
Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.
Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.
A25447
Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026
Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.
Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.
Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055
CTUQQR-Dec22/100002
Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026
Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.
Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.
Not Known
Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026
Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.
Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.
Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.
Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.
Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055
X160111
Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.
Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.
Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055
X16045
Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026
Striha, A orcid.org/0000-0003-3363-8417, Ashcroft, AJ, Hockaday, A et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. p. 169. ISSN 1745-6215